Marine Thinking to Become a Publicly Traded Company on NASDAQ via Combination with Eureka Acquisition Corp. - Eureka Acquisition (NASDAQ:EURKU), Eureka Acquisition Corp - Right (NASDAQ:EURKR)

Applied Materials (AMAT) expects wafer fab equipment (WFE) spending to grow faster through 2030, targeting >2% WFE share gain from 2025-2030 and service revenue >$12B by 2030. The company aims for non-GAAP gross margin of ~54% and operating margin of ~40% by 2030, with plans to distribute 80-100% of free cash flow to shareholders.

Broadcom (AVGO) plans to finance up to $92B in chip purchases for AI labs Anthropic and OpenAI, including $42B in senior debt for Anthropic and up to $50B for OpenAI. The deals aim to secure Broadcom's dominance in the custom AI chip market, with OpenAI and Anthropic as major customers.

BioNTech's experimental mRNA cancer immunotherapy BNT 113, combined with Keytruda, failed to meet the primary endpoint of delaying tumor progression in a late-stage study for head and neck cancer. The trial will continue to assess overall survival as a secondary endpoint. BioNTech, known for its COVID-19 vaccine Comirnaty, is focusing on oncology after a strategic pivot.

GlobalFoundries and TSMC signed a $2 billion deal to produce silicon interposers in the U.S. for AI packaging. GF will expand its New York facility, with production starting in early 2028. The agreement aims to support growing demand for high-performance computing and AI systems, according to GF.

Raytheon, an RTX subsidiary, secured two Pentagon contracts totaling $30.7B to accelerate production of SM-6 and SM-3 Block IB interceptors. The deals span 5-7 years and aim to increase output significantly. Raytheon has also won other contracts to boost Tomahawk and AMRAAM missile production, responding to Pentagon's call to replenish munitions stockpiles.

BioNTech (BNTX) fell 5.22% after reporting initial AHEAD-MERIT trial results. BNT113 plus Merck's Keytruda did not show significant improvement in progression-free survival over Keytruda alone. The trial will continue, focusing on overall survival as the primary endpoint. BNT113 targets HPV16+ head and neck cancer, an area with unmet medical needs.